Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...

The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

Moderna, Baxter, and Pfizer are our top healthcare picks.

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

Ex-vaccine regulator Peter Marks promoted "ineffective therapy that gave patients false hope, eroded trust in the regulatory ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

The Kansas Supreme Court is weighing whether to block a sweeping state law that lets workers easily bypass COVID-19 vaccine ...

Vaccines are a powerful tool of modern medicine, protecting you from diseases that once caused widespread suffering and death ...